Nanoscope Therapeutics Inc.

Nanoscope President and Chief Scientific Officer Samarendra Mohanty, PhD, and Khandan Baradaran, PhD, SVP Regulatory and Quality, will be in Philadelphia this week for Advanced Therapies 2024. Details of presentations and panel discussions are below: Title: Democratizing gene modified cell therapy for neurodegenerative diseases Session: Track 4: Gene Modified Cell Therapy Session Date: Tuesday, November 12, 2024 Session Time: 1:30 PM to 1:50 PM EST  Location: 120B, Pennsylvania Convention Center Presenter: Samarendra Mohanty, PhD, President and Chief Scientific Officer Panel Title: Demonstrating comparability to support regulatory approval Session Title: Track 7: Viral Vector Manufacture Session Date: Tuesday, November 12, 2024 Session Time: 3:30 PM to 4:10 PM EST Location: 121B, Pennsylvania Convention Center Panelist: Khandan Baradaran, PhD, SVP, Regulatory and Quality Panel Title: Post Market Surveillance and Long-term follow up: How do we make sure the needs for patients are met? Session Title: Track 9: Regulatory Affairs & Policy Session Date: Wednesday, November 13, 2024 Session Time: 11:50 AM to 12:30 PM EST Location: 120A, Pennsylvania Convention Center Panelist: Samarendra Mohanty, PhD, President and Chief Scientific Officer Panel Title: Safety in gene editing Session Title: Track 5: Gene Therapy Session Date: Wednesday, November 13, 2024 Session Time: 11:50 AM to 12:30 PM EST Location: 120C, Pennsylvania Convention Center Panelist: Khandan Baradaran, PhD, SVP, Regulatory and Quality Session Title: Track 9: Regulatory Affairs & Policy Session Date: Wednesday, November 13, 2024 Session Time: 3:35 PM EST Location: 120A, Pennsylvania Convention Center Chair: Khandan Baradaran, PhD, SVP, Regulatory and Quality Nanoscope Therapeutics Inc. Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists.  To learn more visit our website: nanostherapeutics.com #genetherapy #biotechnology #clinicaltrials

Nanoscope Therapeutics Inc. President & CSO Samarendra Mohanty is presenting today, November 19th, at CASSS – Sharing Science Solutions CGTP Fall Virtual Summit. Dr. Mohanty's presentations takes place 13:00-14:20 ET. The Summit brings together industry, regulatory, and academic senior-level professionals to address relevant specific challenges in the AAV gene therapy field. For more information about the event: https://lnkd.in/gDNzvnZW Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. Following positive end-of-study results from the RESTORE Phase 2b clinical trial of MCO-010 for RP , the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy For more info about Nanoscope: nanostherapeutics.com #genetherapy #optogenetics #clinicaltrials #retinitispigmentosa

Nanoscope Therapeutics Inc. President and Chief Scientific Officer Samarendra Mohanty will present at the Association for Research in Vision and Ophthalmology (ARVO) Frontiers in Ocular Gene Therapy Research Conference Nov 13-14. He will present as part of the session: Delivery systems including gene transfer strategies, viral vectors and their manufacturing taking place on Wednesday, November 13 from 10:30-11:45am ET. For more information about this virtual event: https://lnkd.in/gfy_sYtq Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. To learn more: nanostherapeutics.com #genetherapy #ophthalmology #retinitispigmentosa

We are honored to welcome Sunil Gupta, MD to the Nanoscope Therapeutics Inc. Board of Directors. Dr. Gupta is a nationally recognized retinal surgeon and a successful entrepreneur who brings deep experience in all phases of drug development and medical devices, including commercialization and manufacturing. “I want to extend a warm welcome to Dr. Gupta and look forward to working with him. He joins us at a pivotal moment in Nanoscope’s journey,” said Glenn Sblendorio, Chairman of the Board. “With an enhanced regulatory pathway, we look forward to utilizing his strategic expertise as well as his network with the retinal community.” Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. To learn more visit: nanostherapeutics.com Read the full press release here:  https://lnkd.in/gMuNXK-r #retina #ophthalmology #leadership  Sulagna Bhattacharya Samarendra Mohanty Michael Marquez Naj Sharif, PhD, DSC Samuel B Barone Khandan Baradaran, PhD Jean Chang

Our Nanoscope Therapeutics Inc. team is growing as we move closer to realizing our mission to change lives for those with vision loss due to retinal degeneration. Today we introduce you to three recent additions to our team. Meet Peri Morris, Associate Director of Manufacturing; Samuel Pacilli, Director of Project Management; and Brett Kiedaisch, Associate Director of Analytical Development. We are pleased and proud that they have chosen to join Team Nanoscope and are already making a significant contribution. Stay tuned for future posts as Nanoscope continues to grow! #genetherapy #ophthalmology #team Sulagna Bhattacharya Samarendra Mohanty

Nanoscope Therapeutics Inc. is proud to share positive 2-year results from the Phase 2b RESTORE randomized, controlled clinical trial of MCO-010 for patients with permanent and severe vision loss from advanced retinitis pigmentosa (RP). Results were presented by Allen Ho, MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope, on October 20, 2024 at the recently concluded American Academy of Ophthalmology 2024 Annual Meeting. During his presentation titled “Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to RP: Two-Year TOPLINE Results From a Phase 2b/3 Randomized, Sham-Controlled Clinical Trial (RESTORE),” Dr. Ho highlighted the measured benefit of ~0.3 LogMAR (3-line, 15-letter equivalent) mean best-corrected visual acuity (BCVA) improvement that was maintained at later time points over the course of the sham-controlled trial.  Additional findings are detailed here in the full press release: https://bit.ly/4f6aSqy To learn more about Nanoscope visit: nanostherapeutics.com #ophthalmology #retinitispigmentosa #clinicaltrials #AAO2024 Samarendra Mohanty Sulagna Bhattacharya

Nanoscope Therapeutics Inc. announces the publication of an important research article of Optogenetic Gene Therapy for Leber Congenital Amaurosis (LCA) in the Journal of Ocular Pharmacology and Therapeutics October 2024 issue. “LCA is a genetic disorder whose pathology is linked to at least 28 different defective genes, appearing within the first few months of life, globally affecting approximately 200,000 newborns. Our research paper demonstrating, for the first time, vision improvement in a mouse model of LCA using a mutation-agnostic gene therapy involving a novel triad fusion protein of MCO-010 represents an important milestone,” said Naj Sharif, PhD, DSC, VP Global Research & Development for Nanoscope. Nanoscope’s MCO-010 platform has not only demonstrated durable, mutation-agnostic efficacy across advanced retinitis pigmentosa and Stargardt clinical programs, but has also demonstrated the potential to be disease-agnostic within Inherited retinal dystrophies (IRDs) in multiple other preclinical models of retinal degenerative diseases including LCA. Authors of the study, all members of the Nanoscope research team, include Adnan Dibas, Subrata Batabyal, PhD, Sanghoon Kim, Michael Carlson, Samarendra Mohanty, and Naj Sharif, PhD, DSC To read the full study: https://lnkd.in/gcK_USur To learn more about Nanoscope Therapeutics and MCO-010 Optogenetic Gene Therapy: nanostherapeutics.com #Genetherapy #retinitispigmentosa #Stargardt #ophthalmology

Nanoscope CEO, Sulagna Bhattacharya is in Washington DC to take part in the Biotechnology Innovation Organization Patient & Health Advocacy Summit where she will share the story of her quest to restore sight to millions of people around the world who suffer from inherited retinal diseases including retinitis pigmentosa and Stargardt Disease. Patient advocacy is at the heart of Nanoscope Therapeutics Inc.’s mission as Sulagna was inspired by a beloved uncle who lost his sight to retinitis pigmentosa. Sulagna will join Leslie J Williams of HC Bioscience, Inc. and Michele Oshman of BIO on the the panel “What’s in a Gene? The Future is Now.” to talk about gene-based innovations that are bringing hope to patients. The panel takes place Thursday, October 24 at 10:30am in the Capital Ballroom, Embassy Suites by Hilton Washington DC Convention Center. We look forward to meeting and sharing our science and passion with the patient advocacy community. For more information about the BIO Patient and Health Advocacy Summit: https://lnkd.in/gPiEkda3 For more information about Nanoscope Therapeutics: nanostherapeutics.com #BIO #genetherapy #patientadvocacy 

It was a terrific time for the Nanoscope Therapeutics Inc. Team in Chicago for the American Academy of Ophthalmology Annual Meeting as well as Eyecelerator and Innovate Retina. The Nanoscope team was honored to present our most recent progress to restore sight for patients with retinal degenerative disease, to reconnect with treasured colleagues and meet new friends who share our mission to bring back the light of hope. #AAO2024 #ophthalmology #retina #

With many members of our team in Chicago today for the American Academy of Ophthalmology Annual Meeting, Nanoscope Therapeutics Inc. is proud to announce a breakthrough publication in Translational Vision Science & Technology (TVST, an ARVO journal) demonstrating that MCO-010 optogenetic treatment of the inner retina arrests further retinal degeneration in an animal model of retinitis pigmentosa (RP), as assessed by optical coherence tomography and immunohistochemical analysis. “MCO-010 is the only broadband, fast, and highly sensitive opsin currently in clinical trials and has demonstrated significant improvement in vision in advanced RP patients. In addition to restoring vision by MCO-010 intravitreal injection, measured by behavioral and electrophysiological assays, this disease-modifying aspect of MCO-010 provides a key therapeutic advantage in optogenetic therapies by targeting bipolar cells in the inner retina,” said Dr. Vinit B. Mahajan, Professor and Vice Chair for Research, Department of Ophthalmology at Stanford University. “This disease-modifying aspect of MCO-010 has also been observed in an animal model of Stargardt disease as well as the nonhuman primate model for geographic atrophy,” said Samarendra Mohanty, Ph.D., President and Chief Scientific Officer of Nanoscope. “We have preliminary evidence of stabilization of retina structure in the RP clinical trial, and we plan to conduct a long-term evaluation of this anatomical biomarker.” Authors of the publication include: Subrata Batabyal, PhD; Sanghoon Kim; Michael Carlson; Darryl Narcisse; Kissaou Tchedre (キサオ テデレ) , PhD., MBA; Adnan Dibas; Naj Sharif, PhD, DSC; Samarendra Mohanty #ophthalmology #retina #optogenetics #AAO2024 For more information read the complete press release here: https://lnkd.in/gQYa-djj